RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+1.73%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$6.85B
AUM Growth
+$6.85B
(+3.3%)
Cap. Flow
+$642M
Cap. Flow
% of AUM
9.38%
Top 10 Holdings %
Top 10 Hldgs %
38.32%
Holding
136
New
16
Increased
27
Reduced
15
Closed
12
Top Buys
| 1 |
Ultragenyx Pharmaceutical
RARE
|
$115M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$94.1M |
| 3 |
Penumbra
PEN
|
$67.7M |
| 4 |
argenx
ARGX
|
$62M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
$52.9M |
Top Sells
| 1 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$153M |
| 2 |
InMode
INMD
|
$19.9M |
| 3 |
IDEAYA Biosciences
IDYA
|
$17.6M |
| 4 |
Guardant Health
GH
|
$11.2M |
| 5 |
AGEN
Agenus
AGEN
|
$10.3M |
Sector Composition
| 1 | Healthcare | 93.33% |
| 2 | Financials | 0.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
SPDR S&P 500 ETF Trust
SPY
$658B
| $423M | 6.17% | 889,739 +16,484 | +2% | +$7.83M |
|
2
Rocket Pharmaceuticals
RCKT
$354M
| $345M | 5.04% | 15,802,802 | – | – |
|
3
Alnylam Pharmaceuticals
ALNY
$58.5B
| $335M | 4.89% | 1,975,879 +292,517 | +17% | +$49.6M |
|
4
Thermo Fisher Scientific
TMO
$186B
| $291M | 4.24% | 435,500 +19,500 | +5% | +$13M |
|
5
Masimo
MASI
$7.59B
| $249M | 3.63% | 849,971 +17,431 | +2% | +$5.1M |
|
|
MRTX
6
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $229M | 3.34% | 1,561,497 +68,965 | +5% | +$10.1M |
|
7
PTC Therapeutics
PTCT
$3.92B
| $211M | 3.08% | 5,293,966 | – | – |
|
8
Illumina
ILMN
$15.8B
| $187M | 2.72% | 490,399 +7,608 | +2% | +$2.89M |
|
|
9
Penumbra
PEN
$10.6B
| $178M | 2.6% | 620,871 +235,677 | +61% | +$67.7M |
|
10
Vericel Corp
VCEL
$1.83B
| $178M | 2.59% | 4,517,570 | – | – |
|
11
Tandem Diabetes Care
TNDM
$845M
| $175M | 2.55% | 1,160,734 | – | – |
|
12
Natera
NTRA
$23.1B
| $174M | 2.54% | 1,862,234 | – | – |
|
13
Establishment Labs
ESTA
$1.2B
| $157M | 2.29% | 2,319,138 | – | – |
|
14
Celldex Therapeutics
CLDX
$1.47B
| $152M | 2.21% | 3,921,579 +12,632 | +0.3% | +$488K |
|
|
RXDX
15
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $129M | 1.88% | 3,264,031 | – | – |
|
16
Globus Medical
GMED
$8.27B
| $121M | 1.76% | 1,670,811 | – | – |
|
17
Cytokinetics
CYTK
$4.23B
| $117M | 1.7% | 2,561,182 +561,182 | +28% | +$25.6M |
|
|
18
Ultragenyx Pharmaceutical
RARE
$2.89B
| $115M | 1.69% | +1,373,284 | New | +$115M |
|
19
Avidity Biosciences
RNA
$5.99B
| $114M | 1.66% | 4,795,000 | – | – |
|
|
ISEE
20
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $112M | 1.64% | 6,722,624 | – | – |
|
|
21
argenx
ARGX
$43.6B
| $111M | 1.62% | 317,447 +177,136 | +126% | +$62M |
|
22
iTeos Therapeutics
ITOS
| $110M | 1.6% | 2,353,015 | – | – |
|
23
10x Genomics
TXG
$1.74B
| $109M | 1.6% | 734,481 | – | – |
|
|
AXNX
24
DELISTED
Axonics, Inc. Common Stock
AXNX
| $109M | 1.59% | 1,943,864 | – | – |
|
|
25
Apellis Pharmaceuticals
APLS
$3.48B
| $94.1M | 1.37% | +1,990,404 | New | +$94.1M |
|